Liver Transplantation Is a Potential Treatment Option for Systemic Light Chain Amyloidosis Patients with Dominant Hepatic Involvement: A Case Report and Analytical Review of the Literature.
Systemic light chain (AL) amyloidosis is caused by abnormal plasma cell clones producing amyloidogenic light chains. The standard treatment is therefore chemotherapy targeting these clones, however, some patients are ineligible due to liver dysfunction. For these patients, preceding liver transplantation (LT) and following chemotherapy is a possible treatment option. We herein report a 58-year-old man with advanced hepatic AL amyloidosis who was successfully treated using this strategy. Previously reported cases treated with LT for this condition were reviewed, however, the outcomes were not favorable. We additionally investigated potential prognostic factors of this treatment approach to improve the outcome of these patients.
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan.
Akihiro
A
Ueno
Nagaaki
N
Katoh
Osamu
O
Aramaki
Masatoshi
M
Makuuchi
Shu-Ichi
S
Ikeda
D000686:Amyloidosis / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood; D007564:Japan; D008107:Liver Diseases / Q000473:pathology*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery*; D010950:Plasma Cells / Q000473:pathology*; D016896:Treatment Outcome
D007147:Immunoglobulin Light Chains